Published in Fundam Clin Pharmacol on January 01, 1996
Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models. J Psychiatry Neurosci (2003) 1.02
Strain and gender differences in the behavior of mouse lines commonly used in transgenic studies. Physiol Behav (2001) 1.81
International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev (1999) 1.74
Long-term individual housing in C57BL/6J and DBA/2 mice: assessment of behavioral consequences. Genes Brain Behav (2005) 1.70
Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am J Psychiatry (1995) 1.59
Tardive dyskinesia: legal and preventive aspects. Can J Psychiatry (1990) 1.47
Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers. Am J Psychiatry (1993) 1.40
Behavioral alterations induced by repeated testing in C57BL/6J and 129S2/Sv mice: implications for phenotyping screens. Genes Brain Behav (2004) 1.32
Intrathecal anesthesia: ropivacaine versus bupivacaine. Anesth Analg (2000) 1.21
Interpretation of knockout experiments: the congenic footprint. Genes Brain Behav (2007) 1.11
A screen for genes induced in the amygdaloid area during cat odor exposure. Genes Brain Behav (2004) 1.01
Intrathecal bupivacaine in humans: influence of volume and baricity of solutions. Anesthesiology (1999) 0.99
Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis. Genes Immun (2005) 0.98
Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones. Nature (1984) 0.98
7-Nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic-like properties in exploratory models of anxiety. Psychopharmacology (Berl) (1997) 0.95
Combined haplotype analysis of the interleukin-19 and -20 genes: relationship to plaque-type psoriasis. Genes Immun (2004) 0.94
Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. Biol Psychiatry (1999) 0.94
CCK in animal and human research on anxiety. Trends Pharmacol Sci (1993) 0.94
Augmentation of the NO-cGMP cascade induces anxiogenic-like effect in mice. J Physiol Pharmacol (2003) 0.91
Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin. Depress Anxiety (2012) 0.91
Wfs1 gene deletion causes growth retardation in mice and interferes with the growth hormone pathway. Physiol Genomics (2009) 0.91
Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. Neuropsychopharmacology (1999) 0.91
Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Br J Dermatol (2007) 0.90
Associations between LSAMP gene polymorphisms and major depressive disorder and panic disorder. Transl Psychiatry (2012) 0.89
Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat. J Neurosci (1997) 0.89
Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry (1999) 0.89
Long-term diazepam treatment produces changes in cholecystokinin receptor binding in rat brain. Eur J Pharmacol (1990) 0.88
Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci (1997) 0.88
Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depress Anxiety (1998) 0.87
IL-10 promoter polymorphisms influence disease severity and course in psoriasis. Genes Immun (2003) 0.87
Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics. Behav Brain Res (1990) 0.87
The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms. Biol Psychiatry (1998) 0.87
The urodynamic effects of intravenous opioids and ketoprofen in humans. Anesth Analg (1998) 0.86
Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers. Eur Neuropsychopharmacol (1991) 0.85
Cholecystokinin2 receptor-deficient mice display altered function of brain dopaminergic system. Psychopharmacology (Berl) (2001) 0.85
A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology (Berl) (1992) 0.84
Neurobiology of panic disorder. J Psychosom Res (1998) 0.84
Clonidine as a sensitizing agent in the forced swimming test for revealing antidepressant activity. J Psychiatry Neurosci (1991) 0.83
BOC-CCK-4, CCK(B)receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze. Neuropeptides (1999) 0.83
Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat. Eur J Pharmacol (1991) 0.83
Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis. Genes Immun (2004) 0.83
Pharmacodynamic dose-response and safety study of cisatracurium (51W89) in adult surgical patients during N2O-O2-opioid anesthesia. Anesth Analg (1996) 0.82
Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol Psychiatry (1996) 0.82
Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment. Naunyn Schmiedebergs Arch Pharmacol (1990) 0.82
Sex differences in the development of diabetes in mice with deleted wolframin (Wfs1) gene. Exp Clin Endocrinol Diabetes (2010) 0.81
Wfs1-deficient animals have brain-region-specific changes of Na+, K+-ATPase activity and mRNA expression of α1 and β1 subunits. J Neurosci Res (2014) 0.80
Gene expression study of IL10 family genes in vitiligo skin biopsies, peripheral blood mononuclear cells and sera. Br J Dermatol (2008) 0.80
The influence of Type A behavior pattern on the response to the panicogenic agent CCK-4. J Psychosom Res (2001) 0.80
8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Psychopharmacology (Berl) (2001) 0.80
Association analysis of IL20RA and IL20RB genes in psoriasis. Genes Immun (2008) 0.80
Alpha-synuclein A30P point-mutation generates age-dependent nigrostriatal deficiency in mice. J Physiol Pharmacol (2008) 0.80
Methylene blue inhibits hippocampal nitric oxide synthase activity in vivo. Brain Res (1999) 0.80
Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats. Naunyn Schmiedebergs Arch Pharmacol (1994) 0.79
The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behav Brain Res (2010) 0.79
L-Arginine abolishes the anxiolytic-like effect of diazepam in the elevated plus-maze test in rats. Eur J Pharmacol (1998) 0.79
High neuroleptic plasma levels in patients manifesting supersensitivity psychosis. Biol Psychiatry (1982) 0.79
CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects. Eur Neuropsychopharmacol (1999) 0.79
Development of a sensitive and specific assay system for cholecystokinin tetrapeptide. Peptides (1997) 0.79
Impaired exploratory behaviour after DSP-4 treatment in rats: implications for the increased anxiety after noradrenergic denervation. Eur Neuropsychopharmacol (1995) 0.79
Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry (1992) 0.79
[Opinion of different professional categories about the intensity of procedural pain in adult intensive care units]. Ann Fr Anesth Reanim (2010) 0.79
MMPI profiles of acute and chronic PTSD in a civilian sample. J Trauma Stress (1996) 0.79
Comparison of behavioral effects after single and repeated administrations of four benzodiazepines in three mice behavioral models. J Psychiatry Neurosci (1992) 0.79
Neuropeptide Y Y(5) receptor antagonist CGP71683A: the effects on food intake and anxiety-related behavior in the rat. Eur J Pharmacol (2001) 0.78
Tardive dyskinesia in a nonpsychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug. Can Med Assoc J (1982) 0.78
Relation of exploratory behaviour to plasma corticosterone and Wfs1 gene expression in Wistar rats. J Psychopharmacol (2009) 0.78
Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Prog Neuropsychopharmacol Biol Psychiatry (1995) 0.78
Effects of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers. J Psychopharmacol (1999) 0.78
Subdiaphragmatic vagotomy does not prevent the anti-exploratory effect of caerulein in the elevated plus-maze. Neuropeptides (1994) 0.78
Relation of exploratory behavior of rats in elevated plus-maze to brain receptor binding properties and serum growth hormone levels. Eur Neuropsychopharmacol (1997) 0.78
Inhibition of nitric oxide synthase causes anxiolytic-like behaviour in an elevated plus-maze. Neuroreport (1995) 0.78
Sedation caused by clonidine in patients with spinal cord injury. Br J Anaesth (2003) 0.78
A randomized trial of sertraline, self-administered cognitive behavior therapy, and their combination for panic disorder. Psychol Med (2010) 0.78
Effect of aging on cholecystokinin-induced panic. Am J Psychiatry (1998) 0.78
Cholecystokinin receptor agonists block the jumping behaviour precipitated in morphine-dependent mice by naloxone. Eur Neuropsychopharmacol (1999) 0.78
Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. J Psychiatry Neurosci (2000) 0.78
Neurobiology of panic disorder. Am J Psychiatry (1989) 0.78
Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy. CNS Drugs (1997) 0.77
Effects of PK 8165, a partial benzodiazepine receptor agonist, on cholecystokinin-induced activation of hippocampal pyramidal neurons: a microiontophoretic study in the rat. Eur J Pharmacol (1985) 0.77
Intracerebroventricular infusion of the CCKB receptor agonist pentagastrin potentiates acoustic startle. Brain Res (1996) 0.77
Comparative studies on the efficacy of psychotherapy, pharmacotherapy, and their combination in depression: was adequate pharmacotherapy provided? J Clin Psychopharmacol (1989) 0.77
Association study of serotonin-2A receptor gene polymorphism and panic disorder in patients from Canada and Germany. Neurosci Lett (2004) 0.77
Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam. Eur Neuropsychopharmacol (2001) 0.77
Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phases. Neuropsychopharmacology (1999) 0.77
An early Phase II clinical trial with followup of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacol Bull (1985) 0.77
An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacology (Berl) (1984) 0.77
The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. Biol Psychiatry (1997) 0.77
A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. J Affect Disord (1994) 0.77
Provocative agents in panic disorder. Therapie (1995) 0.77
Neuronal mechanisms contribute to corticotropin-releasing factor-induced anti-oedema effect in the rat hind paw. Neuropeptides (2000) 0.77
Role of N-methyl-D-aspartic acid and cholecystokinin receptors in apomorphine-induced aggressive behaviour in rats. Naunyn Schmiedebergs Arch Pharmacol (1995) 0.77
Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze. Neuropharmacology (1994) 0.77